{"schema_version":"secwatch.filing_event.v1","accession":"0001764013-25-000091","form_type":"8-K","ticker":"IMVT","cik":"0001764013","company_name":"Immunovant, Inc.","filed_at":"2025-05-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.626765+00:00","generated_at":"2026-05-20T06:09:49.371481+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Immunovant Q4 FY2025 net loss $106.4M, cash $714M; new CEO Eric Venker","bullets":["Net loss of $106.4M ($0.64/share) for Q4 FY2025, vs $75.3M ($0.52/share) a year ago.","Cash and equivalents $714M as of March 31, 2025; runway through GD readout expected in 2027.","Eric Venker, M.D. appointed CEO and Tiago Girao CFO in April 2025 as part of strategic transition.","R&D expenses $93.7M in Q4, up from $66.1M, driven by IMVT-1402 clinical trial costs.","Potentially registrational trials for IMVT-1402 in Sjögren's disease and second GD trial planned summer 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001764013-25-000091","json":"https://secwatch.observer/filing/0001764013-25-000091.json","markdown":"https://secwatch.observer/filing/0001764013-25-000091.md","text":"https://secwatch.observer/filing/0001764013-25-000091.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1764013/000176401325000091/0001764013-25-000091-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1764013/000176401325000091/imvt-20250529.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T06:09:49.371481+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}